Thomas Leggett

Thomas Leggett

Chief Financial OfficeratStoke Therapeutics· In proxies 2023–2025

Pay in FY2025-60% from the year before · Stoke Therapeutics stock +187.8% the same year

Thomas Leggett was paid $1.8M in FY2025 (Dec), down 60%. Stoke Therapeutics stock rose 187.8% that year.

Pay$100 in the stock at the end of FY22 → $344
Pay is from the Summary Compensation Table of each Stoke Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Stoke TherapeuticsPublic company · 3 yr
    • Chief Financial Officer2023 – Present · 3 yrStock in role +222%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?